245 related articles for article (PubMed ID: 19878585)
1. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
2. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Henderson YC; Ahn SH; Kang Y; Clayman GL
Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
[TBL] [Abstract][Full Text] [Related]
6. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
[TBL] [Abstract][Full Text] [Related]
7. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Matsuse M; Mitsutake N; Tanimura S; Ogi T; Nishihara E; Hirokawa M; Fuziwara CS; Saenko VA; Suzuki K; Miyauchi A; Yamashita S
Int J Cancer; 2013 Feb; 132(3):738-43. PubMed ID: 22752848
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
12. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Alzahrani AS; AlQaraawi A; Al Sohaibani F; Almanea H; Abalkhail H
Thyroid; 2012 May; 22(5):536-41. PubMed ID: 22435913
[TBL] [Abstract][Full Text] [Related]
15. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Mol Pathol; 2015 Dec; 99(3):492-7. PubMed ID: 26403329
[TBL] [Abstract][Full Text] [Related]
16. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
17. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Nucera C; Goldfarb M; Hodin R; Parangi S
Biochim Biophys Acta; 2009 Apr; 1795(2):152-61. PubMed ID: 19356676
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Endocrine; 2016 Oct; 54(1):129-138. PubMed ID: 27179656
[TBL] [Abstract][Full Text] [Related]
19.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract][Full Text] [Related]
20. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]